CompaniesD2M Biotherapeutics

D2M Biotherapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (1)
View all

Total Trials

1

As Lead Sponsor

1

As Collaborator

0

Total Enrollment

160

By Phase

PHASE1: 1

By Status

RECRUITING: 1
Clinical Trials Pipeline1 trial
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
2027
Today
NCT06328673
Hover over trial bars to see details

Recent Trials

NCT06328673Lead Sponsor
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
PHASE1Recruiting
160 participants
Started: Mar 1, 2024 · Completed: Mar 1, 2026
Funding History (1)
D
Sep 30, 2020
Filing